secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0001193125-23-294320
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru amends Lincoln Park equity facility to $50M; unveils enobosarm GLP-1 combo plan
--------------------------------------------------------------------------------

- Amended Lincoln Park agreement reduces registered shares from $100M to $50M until $50M sold; only $3.1M sold to date.
- Plans to develop enobosarm to augment fat loss and prevent muscle loss in elderly on GLP-1 drugs.
- Updated corporate presentation includes enobosarm Phase 2b trial design for sarcopenic obese/overweight patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312523294320/0001193125-23-294320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312523294320/d568621d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-294320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer